XOMA Corp

NASDAQ:XOMA  
32.91
+0.41 (+1.26%)
Earnings Announcements

XOMA Earns $2 Million Milestone From Takeda As Mezagitamab Advances Into Phase 2 Development

Published: 11/16/2020 13:33 GMT
(XOMA) - Xoma Earns $2 Million Milestone From Takeda As Mezagitamab Advances Into Phase 2 Development.
Revenue is expected to be $15.89 Million
Adjusted EPS is expected to be $1.09

Next Quarter Revenue Guidance is expected to be $1.8 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.